# Dynatrace, Inc.: financial statements, quarterly

DT · NYSE · CIK 1773383 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/dt.md) · [Financials](/companies/dt/financials.md) · [Filings](/companies/dt/filings.md) · [Insiders](/companies/dt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [352](/filings/0001773383-24-000217.md) | [365](/filings/0001773383-25-000009.md) | [381 d](/filings/0001773383-26-000019.md) | [399](/filings/0001773383-25-000154.md) | [418](/filings/0001628280-25-049225.md) | [436](/filings/0001773383-26-000008.md) | [445 d](/filings/0001773383-26-000019.md) | [477](/filings/0001773383-26-000050.md) | [494](/filings/0001628280-25-049225.md) | [515](/filings/0001773383-26-000008.md) | [532 d](/filings/0001773383-26-000019.md) | [555](/filings/0001773383-26-000050.md) |
| Cost of revenue | $m | [64.4](/filings/0001773383-24-000217.md) | [67.9](/filings/0001773383-25-000009.md) | [71.9 d](/filings/0001773383-26-000019.md) | [74.8](/filings/0001773383-25-000154.md) | [77.8](/filings/0001628280-25-049225.md) | [82.6](/filings/0001773383-26-000008.md) | [85.1 d](/filings/0001773383-26-000019.md) | [85.2](/filings/0001773383-26-000050.md) | [89.8](/filings/0001628280-25-049225.md) | [95.8](/filings/0001773383-26-000008.md) | [101 d](/filings/0001773383-26-000019.md) | [103](/filings/0001773383-26-000050.md) |
| Gross profit | $m | [287](/filings/0001773383-24-000217.md) | [297](/filings/0001773383-25-000009.md) | [309 d](/filings/0001773383-26-000019.md) | [324](/filings/0001773383-25-000154.md) | [340](/filings/0001628280-25-049225.md) | [354](/filings/0001773383-26-000008.md) | [360 d](/filings/0001773383-26-000019.md) | [392](/filings/0001773383-26-000050.md) | [404](/filings/0001628280-25-049225.md) | [420](/filings/0001773383-26-000008.md) | [430 d](/filings/0001773383-26-000019.md) | [451](/filings/0001773383-26-000050.md) |
| Research and development | $m | [74.1](/filings/0001773383-24-000217.md) | [80.1](/filings/0001773383-25-000009.md) | [84.3 d](/filings/0001773383-26-000019.md) | [87.6](/filings/0001773383-25-000154.md) | [95.4](/filings/0001628280-25-049225.md) | [98.3](/filings/0001773383-26-000008.md) | [103 d](/filings/0001773383-26-000019.md) | [108](/filings/0001773383-26-000050.md) | [115](/filings/0001628280-25-049225.md) | [121](/filings/0001773383-26-000008.md) | [131 d](/filings/0001773383-26-000019.md) | [136](/filings/0001773383-26-000050.md) |
| Operating income | $m | [35.3](/filings/0001773383-24-000217.md) | [35.7](/filings/0001773383-25-000009.md) | [23.1 d](/filings/0001773383-26-000019.md) | [42.0](/filings/0001773383-25-000154.md) | [47.0](/filings/0001628280-25-049225.md) | [47.5](/filings/0001773383-26-000008.md) | [42.9 d](/filings/0001773383-26-000019.md) | [62.3](/filings/0001773383-26-000050.md) | [73.0](/filings/0001628280-25-049225.md) | [72.7](/filings/0001773383-26-000008.md) | [37.3 d](/filings/0001773383-26-000019.md) | [71.5](/filings/0001773383-26-000050.md) |
| Income tax | $m | [4.9](/filings/0001773383-24-000217.md) | [(0.3)](/filings/0001773383-25-000009.md) | [(7.8) d](/filings/0001773383-26-000019.md) | [14.1](/filings/0001773383-25-000154.md) | [13.8](/filings/0001628280-25-049225.md) | [(305)](/filings/0001773383-26-000008.md) | [16.4 d](/filings/0001773383-26-000019.md) | [33.4](/filings/0001773383-26-000050.md) | [29.9](/filings/0001628280-25-049225.md) | [44.4](/filings/0001773383-26-000008.md) | [29.4 d](/filings/0001773383-26-000019.md) | [44.2](/filings/0001773383-26-000050.md) |
| Net income | $m | [35.8](/filings/0001773383-24-000217.md) | [42.7](/filings/0001773383-25-000009.md) | [37.9 d](/filings/0001773383-26-000019.md) | [38.6](/filings/0001773383-25-000154.md) | [44.0](/filings/0001628280-25-049225.md) | [362](/filings/0001773383-26-000008.md) | [39.3 d](/filings/0001773383-26-000019.md) | [48.0](/filings/0001773383-26-000050.md) | [57.2](/filings/0001628280-25-049225.md) | [40.1](/filings/0001773383-26-000008.md) | [17.4 d](/filings/0001773383-26-000019.md) | [36.7](/filings/0001773383-26-000050.md) |
| Diluted EPS | $ per share | [0.12](/filings/0001773383-24-000217.md) | [0.14](/filings/0001773383-25-000009.md) | not reported | [0.13](/filings/0001773383-25-000154.md) | [0.15](/filings/0001628280-25-049225.md) | [1.19](/filings/0001773383-26-000008.md) | not reported | [0.16](/filings/0001773383-26-000050.md) | [0.19](/filings/0001628280-25-049225.md) | [0.13](/filings/0001773383-26-000008.md) | not reported | [0.12](/filings/0001773383-26-000050.md) |
| Basic EPS | $ per share | [0.12](/filings/0001773383-24-000217.md) | [0.14](/filings/0001773383-25-000009.md) | not reported | [0.13](/filings/0001773383-25-000154.md) | [0.15](/filings/0001628280-25-049225.md) | [1.21](/filings/0001773383-26-000008.md) | not reported | [0.16](/filings/0001773383-26-000050.md) | [0.19](/filings/0001628280-25-049225.md) | [0.13](/filings/0001773383-26-000008.md) | not reported | [0.13](/filings/0001773383-26-000050.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [702](/filings/0001773383-23-000213.md) | [783](/filings/0001773383-24-000011.md) | [779](/filings/0001773383-25-000065.md) | [930](/filings/0001773383-24-000157.md) | [907](/filings/0001773383-24-000217.md) | [907](/filings/0001773383-25-000009.md) | [1,017](/filings/0001773383-26-000019.md) | [1,247](/filings/0001773383-25-000154.md) | [1,225](/filings/0001628280-25-049225.md) | [1,092](/filings/0001773383-26-000008.md) | [1,097](/filings/0001773383-26-000050.md) | [1,058](/filings/0001773383-26-000050.md) |
| Current assets | $m | [1,102](/filings/0001773383-23-000213.md) | [1,287](/filings/0001773383-24-000011.md) | [1,605](/filings/0001773383-25-000065.md) | [1,424](/filings/0001773383-24-000157.md) | [1,484](/filings/0001773383-24-000217.md) | [1,575](/filings/0001773383-25-000009.md) | [1,931](/filings/0001773383-26-000019.md) | [1,852](/filings/0001773383-25-000154.md) | [1,838](/filings/0001628280-25-049225.md) | [1,867](/filings/0001773383-26-000008.md) | [2,123](/filings/0001773383-26-000050.md) | [1,724](/filings/0001773383-26-000050.md) |
| Total assets | $m | [2,782](/filings/0001773383-23-000213.md) | [2,999](/filings/0001773383-24-000011.md) | [3,410](/filings/0001773383-25-000065.md) | [3,258](/filings/0001773383-24-000157.md) | [3,330](/filings/0001773383-24-000217.md) | [3,735](/filings/0001773383-25-000009.md) | [4,140](/filings/0001773383-26-000019.md) | [4,081](/filings/0001773383-25-000154.md) | [4,082](/filings/0001628280-25-049225.md) | [4,101](/filings/0001773383-26-000008.md) | [4,416](/filings/0001773383-26-000050.md) | [4,109](/filings/0001773383-26-000050.md) |
| Current liabilities | $m | [856](/filings/0001773383-23-000213.md) | [959](/filings/0001773383-24-000011.md) | [1,259](/filings/0001773383-25-000065.md) | [1,051](/filings/0001773383-24-000157.md) | [1,048](/filings/0001773383-24-000217.md) | [1,049](/filings/0001773383-25-000009.md) | [1,381](/filings/0001773383-26-000019.md) | [1,233](/filings/0001773383-25-000154.md) | [1,159](/filings/0001628280-25-049225.md) | [1,193](/filings/0001773383-26-000008.md) | [1,569](/filings/0001773383-26-000050.md) | [1,427](/filings/0001773383-26-000050.md) |
| Total liabilities | $m | [981](/filings/0001773383-23-000213.md) | [1,085](/filings/0001773383-24-000011.md) | [1,394](/filings/0001773383-25-000065.md) | [1,190](/filings/0001773383-24-000157.md) | [1,186](/filings/0001773383-24-000217.md) | [1,182](/filings/0001773383-25-000009.md) | [1,519](/filings/0001773383-26-000019.md) | [1,383](/filings/0001773383-25-000154.md) | [1,303](/filings/0001628280-25-049225.md) | [1,352](/filings/0001773383-26-000008.md) | [1,804](/filings/0001773383-26-000050.md) | [1,659](/filings/0001773383-26-000050.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,802](/filings/0001773383-25-000009.md) | [1,914](/filings/0001773383-25-000009.md) | [2,015](/filings/0001773383-26-000019.md) | [2,068](/filings/0001628280-25-049225.md) | [2,144](/filings/0001773383-26-000008.md) | [2,553](/filings/0001773383-26-000008.md) | [2,621](/filings/0001773383-26-000050.md) | [2,698](/filings/0001773383-26-000050.md) | [2,779](/filings/0001773383-26-000008.md) | [2,749](/filings/0001773383-26-000008.md) | [2,611](/filings/0001773383-26-000050.md) | [2,451](/filings/0001773383-26-000050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [36.9 d](/filings/0001773383-24-000217.md) | [75.7 d](/filings/0001773383-25-000009.md) | [132 d](/filings/0001773383-26-000019.md) | [231](/filings/0001773383-25-000154.md) | [23.7 d](/filings/0001628280-25-049225.md) | [42.2 d](/filings/0001773383-26-000008.md) | [163 d](/filings/0001773383-26-000019.md) | [270](/filings/0001773383-26-000050.md) | [32.0 d](/filings/0001628280-25-049225.md) | [33.8 d](/filings/0001773383-26-000008.md) | [226 d](/filings/0001773383-26-000019.md) | [306](/filings/0001773383-26-000050.md) |
| Capital expenditure | $m | [2.8 d](/filings/0001773383-24-000217.md) | [3.6 d](/filings/0001773383-25-000009.md) | [9.8 d](/filings/0001773383-26-000019.md) | [3.4](/filings/0001773383-25-000154.md) | [3.5 d](/filings/0001628280-25-049225.md) | [4.7 d](/filings/0001773383-26-000008.md) | [14.6 d](/filings/0001773383-26-000019.md) | [7.5](/filings/0001773383-26-000050.md) | [4.2 d](/filings/0001628280-25-049225.md) | [6.5 d](/filings/0001773383-26-000008.md) | [14.0 d](/filings/0001773383-26-000019.md) | [3.2](/filings/0001773383-26-000050.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [45.0](/filings/0001773383-26-000050.md) | not reported | not reported | not reported | [275](/filings/0001773383-26-000050.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [291](/filings/0001773383-23-000213.md) | [291](/filings/0001773383-24-000011.md) | [296](/filings/0001773383-24-000157.md) | [298](/filings/0001773383-24-000217.md) | [299](/filings/0001773383-25-000009.md) | [301](/filings/0001773383-25-000154.md) | [301](/filings/0001628280-25-049225.md) | [303](/filings/0001773383-26-000008.md) | [304](/filings/0001773383-26-000050.md) | [304](/filings/0001628280-25-049225.md) | [303](/filings/0001773383-26-000008.md) | [294](/filings/0001773383-26-000050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 289,002,128 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001773383-26-000050.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.